Radius’ marketing authorisation application (MAA) to the European Medicines Agency (EMA) for the treatment of postmenopausal women with osteoporosis is currently undergoing regulatory review, and we ...

2Q’17 financial results reflect the first 4 weeks of TYMLOS sales in the U.S. Managed care contracts in place for coverage of over 130 million lives for TYMLOS™ (68% of all Commercial and 28% of ...

Radius Health, Inc. RDUS posted a loss of $1.31 per share in the third quarter of 2017, wider than the loss of $1.07 per share in the year-ago quarter and the Zacks Consensus Estimate loss of $1.24.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Radius Health Inc. (NASDAQ: RDUS) shares climbed higher ...